Acorda Therapeutics - Stock Price History | ACOR
Historical daily share price chart and data for Acorda Therapeutics since 2021 adjusted for splits. The latest closing stock price for Acorda Therapeutics as of October 27, 2021 is 4.14.
- The all-time high Acorda Therapeutics stock closing price was 266.95 on January 26, 2015.
- The Acorda Therapeutics 52-week high stock price is 8.66, which is 109.2% above the current share price.
- The Acorda Therapeutics 52-week low stock price is 3.27, which is 21% below the current share price.
- The average Acorda Therapeutics stock price for the last 52 weeks is 4.80.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Acorda Therapeutics Historical Annual Stock Price Data |
| Year |
Average Stock Price |
Year Open |
Year High |
Year Low |
Year Close |
Annual % Change |
| 2020 |
5.8431 |
11.7576 |
14.8770 |
2.6995 |
4.1398 |
-66.17% |
| 2019 |
47.2616 |
97.3005 |
104.7990 |
9.1182 |
12.2376 |
-86.91% |
| 2018 |
141.5511 |
135.8728 |
195.5609 |
77.6245 |
93.4613 |
-27.37% |
| 2017 |
129.1242 |
116.9766 |
180.8638 |
82.7834 |
128.6743 |
14.10% |
| 2016 |
159.1163 |
253.4493 |
253.4493 |
98.6803 |
112.7774 |
-56.05% |
| 2015 |
208.4176 |
243.0114 |
266.9466 |
154.6491 |
256.6287 |
4.67% |
| 2014 |
201.9847 |
173.7253 |
246.3707 |
167.2466 |
245.1710 |
39.97% |
| 2013 |
198.4431 |
150.9898 |
242.5915 |
150.9898 |
175.1650 |
17.46% |
| 2012 |
148.1930 |
146.7307 |
165.6869 |
129.6941 |
149.1302 |
4.28% |
| 2011 |
150.3454 |
161.9676 |
198.4403 |
112.2376 |
143.0114 |
-12.55% |
| 2010 |
189.5533 |
152.6695 |
238.1524 |
150.2699 |
163.5273 |
8.17% |
| 2009 |
140.7639 |
122.6155 |
169.1062 |
100.4199 |
151.1698 |
22.87% |
| 2008 |
140.5590 |
130.4139 |
208.1584 |
92.3815 |
123.0354 |
-6.60% |
| 2007 |
118.0460 |
93.6413 |
153.3893 |
92.0816 |
131.7337 |
38.64% |
| 2006 |
47.2491 |
40.3119 |
120.5159 |
13.3173 |
95.0210 |
0.00% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.046B |
$0.153B |
|
Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA? (dalfampridine) Extended Release Tablets, 10 mg.
|
